首页> 中文期刊> 《临床心身疾病杂志》 >文拉法辛联合小剂量喹硫平治疗难治性抑郁症对照研究

文拉法辛联合小剂量喹硫平治疗难治性抑郁症对照研究

         

摘要

Objective To explores the efficacy and safety of venlafaxine plus small dose quetiapine in treatment-resistant depression (TRD) .Methods Fifty-five TRD patients were randomly assigned to two groups ,research group (n=27) took orally venlafaxine plus small dose quetiap-ine and control group (n= 28) did venlafaxine for 12 weeks .Clinical efficacies were assessed with the Hamilton Depression Scale (HAMD) and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results Effective rate was respectively 81 .5% in research and 53 .6% in control group ,the for-mer was significantly higher than the latter (χ2 =4 .86 ,P<0 .05) .Adverse reactions of both groups were mild .Conclusion Venlafaxine plus small dose quetiapine in TRD has synergism and an evident effect , takes effect more rapidly ,higher safety and better compliance compared with single venlafaxine .%目的:探讨文拉法辛联合小剂量喹硫平治疗难治性抑郁症的临床疗效和安全性。方法将55例难治性抑郁症患者随机分为两组,研究组27例,口服文拉法辛联合小剂量喹硫平治疗;对照组28例,口服文拉法辛治疗。观察12周。采用汉密顿抑郁量表评定临床疗效,副反应量表评定不良反应。结果研究组有效率81.5%,对照组为53.6%,研究组显著高于对照组(χ2=4.86,P<0.05)。两组不良反应均较轻。结论文拉法辛联合小剂量喹硫平治疗难治性抑郁症具有增效作用,疗效显著,起效快,安全性高,依从性好,显著优于单用文拉法辛治疗。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号